Clinical Trials in Multiple Sclerosis (MS) Publications in which BNAC Served as a Core Lab

Phase III Trials

  • Zivadinov R, Dwyer MG, Carl E, Poole EM, Cavalier S, Briassouli P, Bergsland N. Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS. Ther Adv Neurol Dis 2020;13:1756286420970754. [Open article]
  • Khan O, Rieckmann P, Boyko A, Selmaj K, Ashtamker N, Davis MD, Kolodny S and Zivadinov R (2017). "Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study." Mult Scler 23(6): 818-829. [Open article]
  • Zivadinov R, Dwyer MG, Ramasamy DP, Davis MD, Steinerman JR and Khan O (2015). "The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis." J Neuroimaging 25(6): 989-995. [Open article]
  • Zivadinov R, Dwyer M, Barkay H, Steinerman JR, Knappertz V and Khan O (2015). "Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis." J Neurol 262(3): 648-653. [Open article]
  • Clifford DB, Nath A, Cinque P, Brew BJ, Zivadinov R, Gorelik L, Zhao Z and Duda P (2013). "A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes." J Neurovirol 19(4): 351-358. [Open article]
  • Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R and Group GS (2013). "Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis." Ann Neurol 73(6): 705-713. [Open article]

Phase II trials

  • Moore JJ, Massey JC, Ford CD, Khoo ML, Zaunders JJ, Hendrawan K, Barnett Y, Barnett MH, Kyle KA, Zivadinov R, Ma KC, Milliken ST, Sutton IJ and Ma DDF (2019). "Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis." J Neurol Neurosurg Psychiatry 90(5): 514-521. [Open article]
  • Frohman EM, Cutter G, Remington G, Gao H, Rossman H, Weinstock-Guttman B, Durfee JE, Conger A, Carl E, Treadaway K, Lindzen E, Salter A, Frohman TC, Shah A, Bates A, Cox JL, Dwyer MG, Stuve O, Greenberg BM, Racke MK and Zivadinov R (2010). "A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis." Ther Adv Neurol Disord 3(1): 15-28. [Open article]
  • Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G and Zorzon M (2001). "Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS." Neurology 57(7): 1239-1247. [Open article]

PHASE IV TRIALS

  • Zivadinov R, Ramanathan M, Hagemeier J, Bergsland N, Ramasamy DP, Durfee J, Kolb C and Weinstock-Guttman B (2019). "Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis." Mult Scler Relat Disord 36: 101388. [Open article]
  • Zivadinov R, Bergsland N, Carl E, Ramasamy DP, Hagemeier J, Dwyer MG, Lizarraga AA, Kolb C, Hojnacki D and Weinstock-Guttman B (2019). "Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study." J Clin Med 8(3). [Open article]
  • Zivadinov R, Kresa-Reahl K, Weinstock-Guttman B, Edwards K, Burudpakdee C, Bergsland N, Dwyer MG, Khatri B, Thangavelu K, Chavin J, Mandel M and Cohan S (2019). "Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study." J Comp Eff Res 8(5): 305-316. [Open article]
  • Weinstock-Guttman B, Medin J, Khan N, Korn JR, Lathi E, Silversteen J, Calkwood J, Silva D, Zivadinov R and Group M-MS (2018). "Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study." CNS Drugs 32(1): 75-84. [Open article]
  • Zivadinov R, Hagemeier J, Bergsland N, Tavazzi E and Weinstock-Guttman B (2018). "Effect of dimethyl fumarate on gray and white matter pathology in subjects with relapsing multiple sclerosis: a longitudinal study." Eur J Neurol 25(3): 584-e536. [Open article]
  • Zivadinov R, Tavazzi E, Hagemeier J, Carl E, Hojnacki D, Kolb C and Weinstock-Guttman B (2018). "The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study." CNS Drugs 32(8): 763-770. [Open article]
  • Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B and investigators M-M (2018). "Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS." J Neuroimaging 28(4): 399-405. [Open article]
  • Zivadinov R, Bergsland N, Hagemeier J, Carl E, Kolb H, Hojnacki D and Weinstock-Guttman B (2018). "Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures." J Neurol Sci 388: 175-181. [Open article]
  • Zivadinov R, Bergsland N, Hagemeier J, Tavazzi E, Ramasamy DP, Durfee J, Cherneva M, Carl E, Carl J, Kolb C, Hojnacki D and Weinstock-Guttman B (2018). "Effect of switching from glatiramer acetate 20mg/daily to glatiramer acetate 40mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study." J Neurol Sci 387: 152-156. [Open article]
  • Weinstock-Guttman B, Hagemeier J, Kavak KS, Saini V, Patrick K, Ramasamy DP, Nadeem M, Carl E, Hojnacki D and Zivadinov R (2016). "Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation." J Neurol Neurosurg Psychiatry 87(9): 937-943. [Open article]
  • Zivadinov R, Hojnacki D, Bergsland N, Kennedy C, Hagemeier J, Melia R, Ramasamy DP, Durfee J, Carl E, Dwyer MG and Weinstock-Guttman B (2016). "Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years." Eur J Neurol 23(6): 1101-1109. [Open article]
  • Zivadinov R, Dwyer M, Markovic-Plese S, Hayward B, Bergsland N, Heininen-Brown M, Carl E, Kennedy C, Dangond F and Weinstock-Guttman B (2015). "A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis." Ther Adv Neurol Disord 8(2): 59-70. [Open article]
  • Zivadinov R, Dwyer MG, Markovic-Plese S, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Hayward B, Dangond F and Weinstock-Guttman B (2014). "Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study." PLoS One 9(3): e91098. [Open article]
  • Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N and Weinstock-Guttman B (2012). "Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNbeta-1a in multiple sclerosis." Mult Scler 18(8): 1125-1134. [Open article]
  • Zivadinov R, Hojnacki D, Hussein S, Bergsland N, Carl E, Durfee J, Dwyer MG, Kennedy C and Weinstock-Guttman B (2012). "Comparison of Standard 1.5 T vs. 3 T Optimized Protocols in Patients Treated with Glatiramer Acetate. A Serial MRI Pilot Study." Int J Mol Sci 13(5): 5659-5673. [Open article]
  • Zivadinov R, Hussein S, Stosic M, Durfee J, Cox JL, Hashmi K, Abdelrahman N, Garg N, Dwyer MG and Weinstock-Guttman B (2011). "Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis. A case-control diffusion imaging study." Pathophysiology 18(1): 61-68. [Open article]
  • Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M and Horakova D (2009). "Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis." Mult Scler 15(8): 965-976. [Open article]
  • Zivadinov R, Zorzon M, De Masi R, Nasuelli D and Cazzato G (2008). "Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis." J Neurol Sci 267(1-2): 28-35. [Open article]
  • Zivadinov R, Locatelli L, Cookfair D, Srinivasaraghavan B, Bertolotto A, Ukmar M, Bratina A, Maggiore C, Bosco A, Grop A, Catalan M and Zorzon M (2007). "Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy." Mult Scler 13(4): 490-501. [Open article]